



## High-Impact Clinical Trials - 1

Hall D

Moderators: Swapnil Hiremath, MD, MPH, FASN; Meg Jardine, MBBS, PhD

*Note: Full abstracts will be posted online on October 25, 2024.*

- 
- 10:30 a.m. Introduction
- 10:35 a.m. **FR-OR100 Finerenone and Kidney Outcomes in Patients with Heart Failure: The FINEARTS-HF Trial** – [Finnian R. McCausland](#), Muthiah Vaduganathan, Brian Claggett, Ian J. Kulac, Akshay Desai, Pardeep Jhund, Alasdair D. Henderson, Meike Daniela Brinker, Robert M. Perkins, Markus Scheerer, Patrick Schloemer, Carolyn S.P. Lam, Michele Senni, Sanjiv Shah, Adriaan A. Voors, Faiez Zannad, Bertram Pitt, John McMurray, Scott D. Solomon
- 10:50 a.m. Discussant 1 – Ian De Boer, MD, MS
- 11:00 a.m. **FR-OR101 Personalized Recommendations for AKI Using a Kidney Action Team: A Multicenter Randomized Controlled Trial** – [Abinet Mathias Akililu](#), Steven Menez, Yu Yamamoto, Jack Bitzel, Celia P. Corona Villalobos, Kyle D. O'Connor, Kyra A. Shelton, Sophia Faulkner, Amrita Makhijani, Bashar A. Kadhim, Chirag R. Parikh, Francis P. Wilson
- 11:15 a.m. **FR-OR102 Effects of Semaglutide on Kidney Parameters in Patients with Obesity and Nondiabetic CKD** – [Hiddo Jan L. Heerspink](#), Ellen M. Apperloo, Niels Jongs, Secundino Cigarran, Maria Jose Soler, Josep M. Cruzado, Annemarie B. van der Aart, Gozewijn D. Laverman, Jacobien Verhave, Sofia B. Ahmed, Roland E. Schmieder, Christoph Wanner, David Cherney, Jose L. Gorriz
- 11:30 a.m. **FR-OR103 Long-Term Effects of Empagliflozin in CKD** – [William G. Herrington](#), Natalie Staplin, Nikita Agrawal, Richard Haynes, EMPA-KIDNEY Collaborative Group
- 11:45 a.m. **FR-OR104 Efficacy and Safety of HSK21542 for Moderate-to-Severe CKD-Associated Pruritus: A Phase 3 Trial in Hemodialysis Patients** – [Bi-Cheng Liu](#), Jianghua Chen, Aimin Zhong, Yaling Bai, Yan Xu, Bi hu Gao, Yanlin Li, Yu Wang
- 12:00 p.m. **FR-OR105 Efficacy and Safety of Tac or MMF for Children with Steroid-Sensitive but Frequent Relapse or Steroid-Dependent Nephrotic Syndrome: A Nationwide, Multicentre Randomized Study** – [Fei Liu](#), Jingjing Wang, Weili Yan, Jianhua Zhou, Xiaoyun Jiang, Fei Zhao, Xiaochuan Wu, Shuzhen Sun, Mo Wang, Hong Xu, Jing Chen, Cuihua Liu, Shipin Feng, Xuhui Zhong, Haidong Fu, Lingfei Huang, Daqing Ma, Jie Ding, Qing Ye, Jianhua Mao
- 12:15 p.m. Discussant 2 – Keisha L. Gibson, MD, MPH, FASN
- 12:25 p.m. Closing
- 12:30 p.m. Adjourn



**High-Impact Clinical Trials - 2**

Hall D

Moderators: Nisha Bansal, MD, FASN; Matthias Kretzler, MD

*Note: Full abstracts will be posted online on October 26, 2024.*

- 
- 10:30 a.m. Introduction
- 10:35 a.m. **SA-OR91 Impact of Targeted Hyponatremia Correction on 30-Day Mortality and Rehospitalization Rate** – Julie Refardt, Laura Potasso, Anissa Pelouto, Claudia Gregoriano, Markus Koster, Ivana Dora Vodanovic, Dario Norello, Svenja Ravioli, Sadrja Cukoski, Lana Sambula, Nikola Rapsch, Sophie Monnerat, Julia Beck, Deborah R. Vogt, Martina L. Bontognali, Philipp Schuetz, Adrienne A. Zandbergen, Alessandro Peri, Darko Kastelan, Gregor Lindner, Jörg D. Leuppi, Beat Mueller, Volker R. Burst, Ewout J. Hoorn, Mirjam Christ-Crain, The HIT Study Group
- 10:50 a.m. Discussant 1 – Carol A. Pollock, MD, MBBS, PhD
- 11:00 a.m. **SA-OR92 VALIANT: A Randomized, Multicenter, Double-Blind, Placebo (PBO)-Controlled, Phase 3 Trial of Pegcetacoplan for Patients with Native or Post-transplant Recurrent Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)** – Carla M. Nester, Andrew S. Bomback, María Gema Ariceta Iraola, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel N. de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole Van De Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher, Li Li, Zhongshen Wang, Luis López Lázaro, Johan Szamosi, Fadi Fakhouri
- 11:15 a.m. **SA-OR93 Semaglutide Reduced Risks of Major Kidney Outcomes Irrespective of CKD Severity in the FLOW Trial** – Katherine R. Tuttle, Johannes F. Mann, Ekaterina Sokareva, Brian Rayner, Giuseppe Pugliese, Richard E. Pratley, Vlado Perkovic, Kenneth W. Mahaffey, Naoki Kashihara, Ole K. Jeppesen, Janusz Gumprecht, Ricardo Correa-Rotter, David Cherney, Heidrun Bosch-Traberg, Mustafa Arici, Peter Rossing
- 11:30 a.m. **SA-OR94 Pain Coping Skills Training for Patients Receiving Hemodialysis: The HOPE Consortium Randomized Clinical Trial** – Laura M. Dember, Jesse Y. Hsu, Rajnish Mehrotra, Kerri L. Cavanaugh, Sahir Kalim, David M. Charytan, Michael J. Fischer, Manisha Jhamb, Kirsten L. Johansen, William Becker, Francis J. Keefe, David M. White, Paul L. Kimmel, Daniel Cukor, HOPE Consortium
- 11:45 a.m. **SA-OR95 Prospective Randomized Trial of Humacyte's Acellular Tissue Engineered Vessel vs. Autologous Arteriovenous Fistula for Hemodialysis Access** – Mohamad Anas Hussain, Charles K. Ozaki, Ernest E. Moore, Zakaria Khondker, Shamik J. Parikh, Laura E. Niklason
- 12:00 p.m. **SA-OR96 Efficacy and Safety of Dapagliflozin in Patients with CKD Stages 4-5** – Chi-Chih Hung, Yi-Wen Chiu, Shang-Jyh Hwang, DAPA advKD Trial Investigators
- 12:15 p.m. Discussant 2 – David C. Wheeler, MD
- 12:25 p.m. Closing
- 12:30 p.m. Adjourn



**Late-Breaking Science Orals - 1**

Room 6C

Moderators: David H. Ellison, MD, FASN; Areef Ishani, MD, MS

*Note: Full abstracts will be posted online on October 25, 2024.*

- 
- 4:30 p.m. **FR-OR106 Deferoxamine for the Prevention of Cardiac Surgery-Associated AKI: The DEFEAT-AKI Randomized Clinical Trial** – [David E. Leaf](#), Megan L. Krajewski, Edy Y. Kim, Jochen D. Muehlschlegel, Aranya Bagchi, Shahzad Shaefi
- 4:40 p.m. **FR-OR107 Effect of a Perioperative Hypotension Avoidance Strategy vs. a Hypertension Avoidance Strategy on the Risk of AKI** – [Amit X. Garg](#), Maura Marcucci, Meaghan S. Cuerden, Jessica M. Sontrop, PJ Devereaux, Perioperative Ischemic Evaluation-3 (POISE-3) Investigators
- 4:50 p.m. **FR-OR108 Impact of Semaglutide on Infections and COVID-19: Data from the FLOW Trial** – [Brian Rayner](#), Kenneth W. Mahaffey, Johannes F. Mann, Richard E. Pratley, Katherine R. Tuttle, Nicolas Belmar, Heidrun Bosch-Traberg, Ole K. Jeppesen, Minh Chau Tran, Gil Chernin, Peter Rossing
- 5:00 p.m. **FR-OR109 Effect of Semaglutide on Mortality Outcomes in the FLOW Trial** – [Richard E. Pratley](#), Kenneth W. Mahaffey, Johannes F. Mann, Katherine R. Tuttle, Peter Rossing, Thomas Idorn, Jens-Peter David, Heidrun Bosch-Traberg, Ole K. Jeppesen, Willem A. Bax, Pieter Gillard, Mustafa Arici, Minara Shamkhalova, Vlado Perkovic, FLOW Trial Committees and Investigators
- 5:10 p.m. **FR-OR110 Effects of 3.0 mEq/L [K+] Dialysate with Sodium Zirconium Cyclosilicate (SZC) vs. 2.0 mEq/L [K+] Dialysate without SZC on Cardiac Arrhythmia Rates** – [Wolfgang C. Winkelmayr](#), David M. Charytan, Christopher B. Granger, John P. Middleton, Charles A. Herzog, Glenn M. Chertow, James M. Eudicone, James A. Tumlin, ADAPT Investigators
- 5:20 p.m. **FR-OR111 Haemodiafiltration or Haemodialysis for Kidney Failure: Totality of Evidence Based on Individual Patient Data Meta-Analysis from Randomised Controlled Trials** – [Peter J. Blankestijn](#), Robin W. Vernooij, Michiel L. Bots, The CONVINCe Scientific Committee and the HDF Pooling Project Investigators
- 5:30 p.m. **FR-OR112 Exploratory Post Hoc Analysis of the CONVINCe Randomized Controlled Trial: Differential Treatment Effects of Hemodiafiltration (HDF) and Hemodialysis (HD) on Quality of Life** – [Krister Cromm](#), Felix Fischer, Claudia M. Barth, Bernard J. Canaud, Jorgen B. Hegbrant, Giovanni Strippoli, Mark Woodward, Michiel L. Bots, Peter J. Blankestijn, Matthias Rose, The CONVINCe Scientific Committee and CONVINCe Investigators
- 5:40 p.m. **FR-OR113 Varoglutamstat Increases Glomerular Filtration in Elderly Patients without Signs of Proteinuria and Potentially Offers a New Approach to Treat Diabetic Kidney Disease (DKD)** – [Frank Thomas Weber](#), Christine Wenzkowski, Michael Karl Schaeffer, Sylvia Schell-Mader, Antje Meyer, Stefan Tasler, Katharina Fuchs, Asger R. Bihlet, Kevin Carroll, Tobias B. Huber
- 5:50 p.m. **FR-OR114 Replacing Mycophenolate Mofetil by Everolimus in Kidney Transplant Recipients to Increase Vaccine Immunogenicity: The PREPARE-iVAC Trial** – [A. Lianne Messchendorp](#), Jan-Stephan Sanders, The RECOVAC Consortium
- 6:00 p.m. Adjourn



**Late-Breaking Science Orals - 2**

Room 6C

Moderators: Laura M. Dember, MD, FASN; Areef Ishani, MD, MS

*Note: Full abstracts will be posted online on October 26, 2024.*

- 
- 4:30 p.m. **SA-OR97 Safety and Efficacy of Bardoxolone Methyl in Patients with Autosomal Dominant Polycystic Kidney Disease** – [Shuchi Anand](#), Suneeta Chimalapati, Maria E. Montez-Rath, Angie Goldsberry, Melanie Chin, Colin J. Meyer, Samina Khan, Rafael José Esteban de la Rosa, Arlene B. Chapman, Bradley A. Warady, Glenn M. Chertow
- 4:40 p.m. **SA-OR98 Small Molecule Premature Termination Codon Readthrough Therapy: A Phase 2 Pediatric and Adult Trial in Nonsense Mutation Alport Syndrome** – [Daniel P. Gale](#), Detlef Bockenbauer, Melanie M. Chan, Katie Wong, Johannes Pospiech, Tobias Bohnenpoll, Philipp Skroblin, Olivier Radresa, Uwe Andag, Nicole Endlich, Behzad Najafian, Sumit Aggarwal
- 4:50 p.m. **SA-OR99 Associations of APOL1 Biallelic and Monoallelic Kidney Disease Variants with CKDs in West Africans: H3Africa KDRN Study** – [Rasheed A. Gbadegesin](#), Ifeoma I. Ulasi, Yemi R. Raji, Manmak Mamven, Adebowale A. Adeyemo, Titilayo O. Ilori, Adaobi Solarin, Paul L. Kimmel, Frank C. Brosius, Matthias Kretzler, Jeffrey B. Hodgins, Martin Pollak, Barry I. Freedman, Winfred W. Williams, Rulan S. Parekh, Dwomoa Adu, Akinlolu Ojo
- 5:00 p.m. **SA-OR100 Safety and Efficacy of Low-Dose CD19-Targeted CAR T Cells in Refractory Pediatric Systemic Lupus Erythematosus (SLE)** – [Xue He](#), Yingzi Zhang, Fei Liu, Qiu-yu Li, Jingjing Wang, Jianhua Mao
- 5:10 p.m. **SA-OR101 Felzartamab for IgA Nephropathy: Final Results of the IGNAZ Study** – [Jonathan Barratt](#), Jürgen Floege, Richard A. Lafayette, Brian M. Schwartz, Uptal D. Patel, Paul Manser, Lisa Kivman, Stefan Haertle, Nicola Faulhaber, Anjali G. Thakur, Sean Barbour
- 5:20 p.m. **SA-OR102 Long-Term Results from the ORIGIN Phase 2b Study of Atacicept for the Treatment of IgA Nephropathy (IgAN)** – [Jonathan Barratt](#), Sean Barbour, Robert M. Brenner, Kerry Cooper, Xuelian Wei, Necmi Eren, Jürgen Floege, Vivekanand Jha, Sung Gyun Kim, Bart D. Maes, Richard K. Phoon, Harmeet Singh, Vladimir Tesar, Richard A. Lafayette, ORIGIN Phase 2b Study Team
- 5:30 p.m. **SA-OR103 SC0062, a New Selective Endothelin Receptor Type A Antagonist in IgA Nephropathy** – [Hiddo Jan L. Heerspink](#), Xiaoying Du, Yan Xu, Yanning Zhang, Bin Liu, Guangyu Bi, Chengyun Xu, Qun Luo, Henglan Wu, Jianxin Wan, Liou Cao, Rong Wang, Qiuling Fan, Hong Cheng, Lixia Xu, Jiye Huang, Aimin Zhong, Qingfeng Peng, Yongjiang Hei, Yiwei Wang, Bo Zhou, Liqin Zhang, Jianghua Chen, 2-SUCCEED Study Group & BioCity Team
- 5:40 p.m. **SA-OR104 Out-of-Sequence Placement of Deceased Donor Kidneys Is Exacerbating Inequities** – [Miko Yu](#), Syed A. Husain, Joel T. Adler, Lindsey Maclay, Jesse D. Schold, Sumit Mohan
- 5:50 p.m. **SA-OR105 Xenotransplantation and Physiologic Homeostasis: Case Report of a First Living Human Recipient** – [Sul A Lee](#), Marie-Camille Lafargue, Winfred W. Williams, Hannah M. Gilligan, Kassem Safa, Abraham Cohen Bucay, Pitchaphon Nissaisorakarn, Ayman Al Jurdi, Harald Jüppner, Susan Low, Michael Curtis, Leonardo V. Riella, Mass General Kidney Transplant Team and eGenesis Team
- 6:00 p.m. Adjourn



**Late-Breaking Clinical Trials Posters**

Exhibit Hall

*Note: Full abstracts will be posted online on October 24, 2024.*

- TH-PO1165 **Remote Ischemic Preconditioning Can Prevent Contrast-Induced AKI (CIAKI) by Reducing Neutrophil Extracellular Traps (NETs)** – [Mengqing Ma](#), Xin Wan, Changchun Cao
- TH-PO1166 **Advancing Community Care and Access to Follow-Up after AKI Hospitalization: The AFTER AKI Randomized Controlled Trial** – [Neesh I. Pannu](#), Kerry Mcbrien, Coralea Bignell, Eleanor C. Benterud, Taylor Palechuk, Tyrone Harrison, Braden J. Manns, Matthew T. James
- TH-PO1167 **Acute Kidney Disease Detection in an Outpatient Setting: A Pragmatic Randomized Controlled Trial** – [David R. Chang](#), Hsiu-Yin Chiang, Yu-Ting Lin, Zi-Han Lin, Hung chieh Yeh, Chin-Chi Kuo
- TH-PO1168 **Validation of a Combined Biomarker Including FGF-23, Erythropoietin, and Klotho for Development AKI and Clinical Outcomes in Patients in the Intensive Care Unit (ICU)** – [Luis Michea](#), Luis Toro, Veronica Rojas, Daniela Ponce, Carlos Irarrazabal, Danilo Fischer, Carlos Romero, Julia Guerrero
- TH-PO1169 **Evaluation of the Anticoagulant Effect of Effluent Ionized Calcium iCa to Measure Regional Citrate Anticoagulation (RCA) Performance vs. Post-filter Ionized Calcium iCa: A Single-Center Non-inferiority Randomized Controlled Trial (RCT)** – [Niroj Mali](#), Ping Fu
- TH-PO1170 **Sodium Zirconium Cyclosilicate (SZC) to Enable Renin Angiotensin-Aldosterone System Inhibitor (RAASi) Use for Diabetic Kidney Disease: The CRYSTAL Study** – [Weiming Wang](#), Leyi Gu, Xiujuan Zang, Na Liu, Yangbin Pan, Chunming Jiang, Ying Li, Gengru Jiang, Zhiguo Mao, Jun Xue, Rong Zhou, Hao Xu, Jian Liu
- TH-PO1171 **Can Exogenous Ketones Prevent the Effects of High Salt on Renal Vascular Resistance during Sympathoexcitation?** – [Soolim Jeong](#), Nina L. Stute, Sofia O. Sanchez, Orlando M. Gutierrez, Zachary Schlader, Austin Robinson
- TH-PO1172 **Immunosuppression Minimization In Kidney Transplant Recipients with Transplant Excellence Based on the TruGraf Test** – [Venkat Ram Peddi](#), Parul S. Patel, Allison Gourley, Jalyn R. Vickroy
- TH-PO1173 **Social Network Interventions to Reduce Racial/Ethnic Living Donor Kidney Transplants (LDKT) Disparities: Preliminary Results from the Friends and Family of Kidney Transplant Patients Study** – [Jonathan Daw](#), Jennifer M. Kirk, Ashton Verdery, Selena E. Ortiz, Rhiannon D. Reed, Jayme E. Locke, David Kloda, Brian A. McCauley, Deirdre L. Sawinski, Peter P. Reese
- TH-PO1174 **VIRENO Study: A Novel Approach for Early Outcome Prediction after Kidney Transplantation** – [Patrick Affeldt](#), Katharina Burkert, Rabi R. Datta, Franziska Grundmann, Martin Kann, Florian Klein, Christine E. Kurschat, Dirk L. Stippel, Michael N. Thomas, Katharina Tuschen, Alexander Weidemann, Benjamin Wilde, Veronica Di Cristanziano, Roman-Ulrich Mueller, The VIRENO Study Group
- TH-PO1175 **Phase I/IIa Trial of Autologous Regulatory T Cell Therapy Together with Donor Bone Marrow Infusion in Kidney Transplantation** – [Rainer Oberbauer](#), Moritz Muckenhuber, Jasmin Mucha, Roman Reindl-Schwaighofer, Andreas Heinzl, Anna M. Weijler, Gabriela Berlakovich, Nina Worel, Michael Wolzt, Thomas Lion, Matthias Edinger, Thomas Wekerle



**KIDNEY  
WEEK** 20  
24

October 23-27 | San Diego, CA

### Late-Breaking Clinical Trials Posters (cont.)

- TH-PO1176 A Hypertension Management App for Salt Restriction in Patients with CKD: The CureApp-CKD Trial** – Takayuki Kawaoka, Yusuke Sakaguchi, Yuki Kawano, Tatsufumi Oka, Yohei Doi, Isao Matsui, Jun-Ya Kaimori, Yoshitaka Isaka
- TH-PO1177 Rilparencel Autologous Cell Therapy in Patients with Diabetes and Advanced CKD: Phase 2 Interim Results** – Joseph Stavas, Arnold L. Silva, Theodore F. Saad, Emily L. Butler, Navdeep Tangri, Bruce F. Culleton
- TH-PO1178 Radiofrequency Renal Denervation in Patients with Severe CKD, Including Patients on Dialysis: Analysis from the Global SYMPPLICITY Registry DEFINE** – Markus P. Schlaich, Felix Mahfoud, Krzysztof Narkiewicz, Luis M. Ruilope, Faisal Sharif, Flavio L. Ribichini, Michael Böhm
- TH-PO1179 Impact of Adjunctive Active Vitamin D on Kidney Function during Treatment of Secondary Hyperparathyroidism (SHPT) with Extended-Release Calcifediol (ERC) in Nondialysis-Dependent CKD (ND-CKD)** – Akhtar Ashfaq, John Choe, Stephen A. Strugnell, Nilay Patel, Stuart M. Sprague, Keith C. Norris, Edgar V. Lerma, Charles W. Bishop, OPKO Health
- TH-PO1180 Evaluation of an At-Home Creatinine Assay for CKD Management: Pilot Method Comparison Study and Clinical Implications** – Vissaagan Gopalakrishnan, Amrutha Anilkumar, Supriya Chavan, Bharath B. Rangaswamy, Richard E. Williams, Anh N. Hoang, James Januzzi
- TH-PO1181 Efficacy and Safety of AND017 for Treatment of Anemia in Dialysis-Dependent CKD** – Yusha Zhu, Xiaoqiang Ding, Suzanne Wilson, Xiaolu Li, Ping Du, Qi Zhu, Geoffrey A. Block, Pablo E. Pergola
- TH-PO1182 Effect of Hemodialysis with Citrate on Vascular Calcification** – W. Charles O'Neill, Jose E. Navarrete
- TH-PO1184 Double vs. Single Icodextrin Dose in Older Incident Patients on Incremental Continuous Ambulatory Peritoneal Dialysis (CAPD): Results from the DIdo (Double Icodextrin Dose) Study** – Eric Goffin, Clémence Béchade, Cécile Courivaud, Karlien Francois, Bert Bammens, Michel Y. Jadoul, Olivier Devuyst, Martin E. Wilkie, Aurélie Bertrand, Thierry Lobbedez, DIdo Study Group
- TH-PO1185 Community Health Worker Intervention for Latinos Receiving Hemodialysis: A Randomized Controlled Trial** – Lilia Cervantes, Neil R. Powe, Daniel Cukor, Brenda Beaty, Lauren Mcbeth, Romana Hasnain, Michel Chonchol
- TH-PO1186 Cost Utility of High-Dose Online Hemodiafiltration Compared with High-Flux Hemodialysis: Economic Evaluation of the Multinational, Randomized Controlled CONVINCe Trial** – Aniek E.M. Schouten, Felix Fischer, Peter J. Blankestijn, Robin W. Vernooij, Carinna Hockham, Giovanni Strippoli, Bernard J. Canaud, Jorgen B. Hegbrant, Claudia M. Barth, Krister Cromm, Andrew Davenport, Matthias Rose, Mark Woodward, Michiel L. Bots, G. A. de Wit, Geert Frederix, Miriam P. van der Meulen, The CONVINCe Scientific Committee
- TH-PO1187 Ferric Citrate for the Prevention of Renal Failure in Adults with Advanced CKD: The FRONTIER Trial** – Geoffrey A. Block, Steven K. Burke, Martha Block, Stephanie Brillhart, Amanda Leppink, Gerard J. Smits, Mohammad R. Mizani, Pablo E. Pergola, F. David Newby, Varshasb Broumand, Bryce S. Foote, Mary O. Dittrich
- TH-PO1188 Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia** – Geoffrey A. Block, Glenn M. Chertow, Guru Reddy, Sanjay S. Mourya, Martha Block, Steve Hasal, Shalabh Gupta, Pablo E. Pergola



**Late-Breaking Clinical Trials Posters (cont.)**

- TH-PO1189 Which Patients Benefit the Most from Hemodiafiltration Compared with Hemodialysis? Prediction of Individualized Treatment Effects** – [Peter J. Blankestijn](#), Robin W. Vernooij, Michiel L. Bots, The CONVINCE Study Group
- TH-PO1190 Amino Acids Supplementation and Exercise Intervention in Hemodialysis Patients: Effects on Muscle and Fatigue, A Randomized Controlled Trial** – [Emad Samaan](#), Ammar Y. Ali, Ahmed R. Moustafa, Mirna Shahin, Hala I. Gamaleldin, Sara M. Abdelgawad, Alaa A. Awad, Mohamed Elgamal, Hanan M. Elberashi, Alaa A. Sabry
- TH-PO1191 Long-Term Experience of Treating CKD-Associated Pruritus (CKD-aP) with Difelikefalin at a Large Dialysis Organization in the United States** – [Rachel A. Lasky](#), Despina Ruessmann, Linda Ficociello, Maria Gil Mir, Hans-Juergen Arens, Michael S. Anger
- TH-PO1192 Dialysis Symptom Control-Pruritus Outcome Trial (DISCO-POT): A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Crossover Trial** – [David Thomas Collister](#), Kathy Cherepak, Navdeep Tangri, Michael Walsh, DISCO-POT Investigators
- TH-PO1193 Abstract Withdrawn**
- TH-PO1194 Real-World Effectiveness of Patiromer among Hemodialysis (HD) Patients: 1-Year Follow-Up on a Retrospective Cohort** – [Meijiao Zhou](#), Despina Ruessmann, Linda Ficociello, Maria Gil Mir, Hans-Juergen Arens, Michael S. Anger
- TH-PO1195 SPARKLE: A Multicenter, Open-Label Study to Evaluate the Safety and Diagnostic Efficacy of ACE-MBCA in Patients with Known or Suspected Focal Liver Lesions and Severe Renal Impairment** – [Anna Laura Croci Chicocchini](#), Andreas L. Norlin, Nadilka Hettiarachchige, David I. Ortiz Melo
- TH-PO1196 Azithromycin for the Prevention of Hemolytic Uremic Syndrome in Shiga Toxin-Positive Diarrhea: A Proof of Concept** – [Gianluigi Ardissino](#), Letizia Dato, Maria Cristina Mancuso, Thomas Ria, Laura Daprai, Alessandra Gazzola, Alessandra Bazzucchi, Michela Piccoli, Ilaria Possenti, Alice Monzani, Laura Martelli, Angela Amoroso, Giovanni Raimondo Pieri, Antonio Vergori, Sonia Monticone, Marta Cerutti, Cristina Partenope, Anna Elisabetta Bussolini, Alessandra C. Ferrari, Elisa La Barba, Giulia M. Smylie, Simone V. Benatti, Mario V. Luini, ItalKid-HUS Network
- TH-PO1197 GFR Changes Following Urinary Tract Infection (UTI) in Children with Vesicoureteral Reflux (VUR)** – [David S. Hains](#), Michelle C. Starr, Andrew L. Schwaderer
- TH-PO1198 Effect of Pravastatin on Kidney Disease Outcomes in Adult Patients with Early-Stage Autosomal Dominant Polycystic Kidney Disease** – [Berenice Y. Gitomer](#), Wei Wang, Anna Ostrow, Kristen L. Nowak, Diana George, Erin R. Coleman, Nayana Patel, Anna Jovanovich, Jelena Klawitter, Zhiying You, Michel Chonchol
- TH-PO1199 Outcomes of the DUPLEX Trial in Patients with Genetic Focal Segmental Glomerulosclerosis (gFSGS)** – [Jennifer Lai Yee](#), Wu Gong, Julia K. Inrig, Michelle N. Rheault, Radko Komers, Howard Trachtman
- TH-PO1200 RGLS8429 Increases Urinary PC1 and PC2 and May Reduce Height-Adjusted Total Kidney Volume (htTKV) in Patients with ADPKD** – [Alan S.L. Yu](#), Rekha Garg, Keith A. Bellovich, Arnold L. Silva, Claire S. Padgett, Edmund C. Lee, Tania M. Valencia, Timothy L. Kline, Adriana Gregory, Kevin Carroll, Vishal Patel



**Late-Breaking Clinical Trials Posters (cont.)**

- TH-PO1201 Stopping Eculizumab Treatment Safely in Atypical Haemolytic Uraemic Syndrome (SETS aHUS): A Multicentre, Open-Label, Prospective, Single-Arm Trial of the Safety and Impact of Eculizumab Withdrawal** – Neil S. Sheerin, Sally A. Johnson, Edwin K. Wong, Luke Vale, Michal Malina, Giovany Orozco Leal, Ciara A. Kennedy, Sarah Dunn, David Kavanagh
- TH-PO1202 Rituximab for Adult-Onset Frequently Relapsing or Steroid-Dependent Nephrotic Syndrome: A Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial** – Yoshitaka Isaka, Shoichi Maruyama, Mika Sakaguchi, Hiroki Hayashi, Yusuke Kaida, Shin Goto, Tatsuo Tsukamoto, Akito Maeshima, Yoichiro Ikeda, Norihiko Sakai, Naoki Sawa, Kengo Furuichi, Kunihiro Yamagata, Yusuke Sakaguchi, Maki Shinzawa, Takehiko Wada, Yugo Shibagaki, Keiju Hiromura, A-TEAM
- TH-PO1203 AMPLITUDE: A Phase 2/3 Adaptive Trial of Inaxaplin in APOL1-Mediated Kidney Disease** – Glenn M. Chertow, George Manos, Ogo I. Egbuna
- TH-PO1204 Zanubrutinib for the Treatment of Primary Membranous Nephropathy (PMN): Results of a Single-Arm Feasibility Study** – Richard A. Lafayette, Sean Barbour, Yanyan Chen, Zhen Yao, Shengnan Chen, Guisen Li, Ming-Hui Zhao
- TH-PO1205 Phase II Results of an Investigational RNA Therapeutic to Complement Factor B, IONIS-FB-LRx, for Treatment of IgA Nephropathy** – Sean Barbour, Michelle A. Hladunewich, Angela Makris, Sven-Jean Tan, Richard A. Robson, Muh Geot Wong, Jason Choo Chon Jun, Ashley Frazer-Abel, Lixuan Yin, Terry Barrett, Richard Geary, Eugene Schneider, Jon L. Ruckle, Michael Mccaleb, Gary T. Brice
- TH-PO1206 Single-Center, Phase 2, Open-Label Trial Evaluating the Efficacy and Safety of Obinutuzumab in Treatment of Immunosuppression-Resistant Primary FSGS, or Contraindication to High-Dose Corticosteroids** – Ladan Zand, Eddie L. Greene, Wisit Cheungpasitporn, Maria Jose Vargas-Brochero, Miriam Machado, Sanjeev Sethi, Pierre M. Ronco, Fernando C. Fervenza